ACGT

ACGT aims to present the 'next-step' in cancer research and fill-in the technological gaps of clinical trials targeting two forms of cancer: breast cancer and paediatric nephroblastoma. ACGT will develop a Biomedical GRID infrastructure supporting seamless mediation services for sharing clinical and genomic expertise. It will help to identify quicker and more efficiently the characteristics that determine what form of treatment best suits which patient.

ACGT aims to provide researchers and patients with the best means and resources to fight cancer. ACGT is working towards the rapid identification of cancer profiles and best treatments. The ACGT project will:

  • Define common standards of data storage at each level of investigation.
  • Develop new ontologies for cross-referencing terms and their biological contexts.
  • Implement a bio-medical GRID infrastructure offering seamless mediation services for sharing data and dataprocessing.

ACGT will therefore deliver a unifying infrastructure allowing cancer researchers to share their data and to benefit from the innovative informatics tools that are being developed by other researchers.

For further information, please visit:
http://www.eu-acgt.org

Project co-ordinator:
ERCIM EEIG

Partners:

  • ERCIM EEIG - Institut National de Recherche en Informatique et en Automatique - Healthgrid (FR)
  • Foundation for Research and Technology Hellas - A. Persidis & SIA O.E. - University of Crete - Institute of Communications and Computer Systems (GR)
  • University van Amsterdam - Philips Electronics Nederland B.V. (NL)
  • Association Hospitaliere de Bruxelles – Centre Hospitalier Universitaire Bordet – Custodix - Facultes Universitaires Notre-Dame de la Paix (BE)
  • Institut Suisse de Bioinformatique (CH)
  • Lunds Universitet (SE)
  • Universidad de Malaga - Universidad Politechnica de Madrid (ES)
  • Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung - Unisersitaet Hannover - Universitaet des Saarland - Universitaet Hamburg (DE)
  • Instytut Chemii Biooganicznej pan w Poznaniu (PL)
  • S.C. SIVECO ROMANIA SA (RO)
  • The Chancellor, Masters and Scholars of the University of Oxford (UK)
  • Hokkaido University (JP)
  • Istituto Europeo di Oncologia s.r.l. (IT)

Timetable: from 02/06 - to 01/10

Total cost: € 16. 747.206

EC funding: € 11. 887.000

Instrument: Integrated Project

Project Identifier: IST-2004-026996

Most Popular Now

Study Finds One-Year Change on CT Scans …

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease...

Yousif's Story with Sectra and The …

Embarking on healthcare technology career after leaving his home as a refugee during his teenage years, Yousif is passionate about making a difference. He reflects on an apprenticeship in which...

New AI Tools Help Scientists Track How D…

Artificial intelligence (AI) can solve problems at remarkable speed, but it’s the people developing the algorithms who are truly driving discovery. At The University of Texas at Arlington, data scientists...

AI Tool Offers Deep Insight into the Imm…

Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily...

Highland to Help Companies Seize 'N…

Health tech growth partner Highland has today revealed its new identity - reflecting a sharper focus as it helps health tech companies to find market opportunities, convince target audiences, and...